10/10/01 WED 14:06 FAX 7033088724	PTO TC 1600	4 001

TRANSMISSION OK		
TX/RX NO CONNECTION TEL SUBADDRESS CONNECTION ID	4048 919495676600	
ST. TIME USAGE T PGS. RESULT	10/10 14:05 01'01 3 OK	



United States Patent and Trademark Office

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
WWW.uspto.gov

Fax Cover Sheet

Date: 10 Oct 2001

Interview Summary.

Art Unit: 1655
Phone No.: 703/305-0761
Return Fax No.: 703/308-8724
CC:
For Reply Per Your Request



United States Patent and Trademark Office

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 2023I
www.uspto.gov

Fax Cover Sheet

Date: 10 Oct 2001 From: Diana B. Johannsen To: Paul Veravanich Art Unit: 1655 Application/Control Number: 09/499,006 Phone No.: 703/305-0761 Fax No.: (949)567-6600 Return Fax No.: 703/308-8724 Voice No.: (949)567-2300 CC: Re: ☐ For Reply ☐ Per Your Request For Review ☐ For Comment ☐ Urgent Comments: Interview Summary.

Number of pages 3 including this page

STATEMENT OF CONFIDENTIALITY

This facsimile transmission is an Official U.S. Government document which may contain information which is privileged and confidential. It is intended only for use of the recipient named above. If you are not the intended recipient, any dissemination, distribution or copying of this document is strictly prohibited. If this document is received in error, you are requested to immediately notify the sender at the above indicated telephone number and return the entire document in an envelope addressed to:

Assistant Commissioner for Patents

Applicant(s) 09/499,006 BAGGOT, DR. PADDY JIM Interview Summary Art Unit Examiner 1655 Diana B. Johannsen All participants (applicant, applicant's representative, PTO personnel): (3) Paddy Jim Baggot. (1) Diana Johannsen. (4)_____. (2) Paul Veravanich. Date of Interview: 10/10/01 Type: a) ☐ Telephonic b) ☐ Video Conference c) Personal [copy given to: 1) applicant 2) applicant's representative] Exhibit shown or demonstration conducted: d) Yes e)⊠ No. If Yes, brief description: _____. Claim(s) discussed: all pending. Identification of prior art discussed: Galjaard (Ballieres Clin. Obst. Gyn. 1(3):547-567 [9/1987]) . Agreement with respect to the claims f) was reached. g) was not reached. h) N/A. Substance of Interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments: See Continuation Sheet . (A fuller description, if necessary, and a copy of the amendments which the examiner agreed would render the claims allowable, if available, must be attached. Also, where no copy of the amendments that would render the claims allowable is available, a summary thereof must be attached.) i) It is not necessary for applicant to provide a separate record of the substance of the interview(if box is checked). Unless the paragraph above has been checked, THE FORMAL WRITTEN REPLY TO THE LAST OFFICE ACTION MUST INCLUDE THE SUBSTANCE OF THE INTERVIEW. (See MPEP Section 713.04). If a reply to the last Office action has already been filed, APPLICANT IS GIVEN ONE MONTH FROM THIS INTERVIEW DATE TO FILE A STATEMENT OF THE SUBSTANCE OF THE INTERVIEW. See Summary of Record of Interview requirements on reverse side or on attached sheet.

Examiner Note: You must sign this form unless it is an

Attachment to a signed Office action.

Continuation Sheet (PTO-413)

Continuation of Substance of Interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments: Proposed amendments to the claims were discussed briefly, with the examiner noting that it remains unclear as to whether the claims are intended to encompass, e.g., methods of comparing metabolite levels to look for correlations with chromosomal abnormalities, methods of identifying/treating particular chromosomal abnormalities based on the presence of particular patterns of metabolite levels, etc. Applicant's representative noted that one embodiment of the invention involved comparing patterns of metabolite levels in normal individuals with patterns in individuals known to have a chromosomal abnormality. Dr. Baggot provided an overview of the invention, noting that the invention differs from the art in that it does not involve detecting abnormalities in the level of one metabolite as an indicator of a particular disease related to defects in a single enzyme. Dr. Baggot indicated that the invention requires detection of a multitude of metabolites in order to provide a comprehensive picture of the state of a patient, and noted that the invention might be used in drawing preliminary conclusions regarding an abnormality in a patient that could subsequently be verified by, e.g., chromosomal analysis. The examiner noted that claims limited to detection of particular, novel combinations of metabolites (e.g., the combination of claim 4) as indicators of Down Syndrome could be considered after final and might be allowable pending an updated search, but that the invention as described by Dr. Baggot differed from the claimed invention and consideration of claims drawn to this invention would require further search and consideration. The examiner also noted that claims requiring detection of, e.g., at least two of the metabolites of claim 4 would require a search of each combination to determine whether each combination was novel and non-obvious. .